Xeris Biopharma Holdings (XERS) Net Cash Flow (2020 - 2026)
Xeris Biopharma Holdings' (XERS) quarterly Net Cash Flow came in at $708000.0 in Q1 2026, up 105.37% YoY from $344741.3 in Q1 2025, and down 96.36% on a QoQ basis from $19.4 million in Q4 2025.
Xeris Biopharma Holdings (XERS) Net Cash Flow (2020 - 2026) Analysis & Trends
Xeris Biopharma Holdings (XERS) has 7 years of Net Cash Flow data on file, last reported at $708000.0 in Q1 2026.
- Quarterly Net Cash Flow rose 105.37% year-over-year to $708000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $53.2 million (up 1322.61% YoY) and the FY2025 annual result came in at $39.3 million, up 866.07% from the prior year.
- Net Cash Flow retreated to $708000.0 in Q1 2026, from $19.4 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $42.2 million in Q4 2022 to a low of -$71.0 million in Q1 2023.
- A 5-year average of $2.9 million and a median of $708000.0 in 2026 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2023 — Net Cash Flow sank 294.47% — and 2024, when it jumped 5751.85%.
- Tracing XERS's Net Cash Flow over 5 years: stood at $42.2 million in 2022, then tumbled by 49.99% to $21.1 million in 2023, then plunged by 41.3% to $12.4 million in 2024, then soared by 56.95% to $19.4 million in 2025, then tumbled by 96.36% to $708000.0 in 2026.
- The last three Net Cash Flow figures came in at $708000.0 (Q1 2026), $19.4 million (Q4 2025), and $32.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn | -81.00 Mn |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn | -458.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -881.03 Mn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 523.50 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -912.40 Mn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 64.40 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 93.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Xeris Biopharma Holdings | 1.51 Bn | 1.39 Bn | 79.59 Mn | 10.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.00 Mn |
| Jun 30, 2026 | 10.00 Mn |
| Mar 31, 2026 | 708,000.00 |
| Mar 31, 2026 | 708,000.00 |
| Dec 31, 2025 | 19.44 Mn |
| Dec 31, 2025 | 19.44 Mn |
| Sep 30, 2025 | 32.21 Mn |
| Sep 30, 2025 | 32.21 Mn |
| Jun 30, 2025 | 845,000.00 |
| Jun 30, 2025 | 845,000.00 |
| Mar 31, 2025 | -13.18 Mn |
| Mar 31, 2025 | -13.18 Mn |
| Dec 31, 2024 | 12.39 Mn |
| Dec 31, 2024 | 12.39 Mn |
| Sep 30, 2024 | 1.53 Mn |
| Sep 30, 2024 | 1.53 Mn |
| Jun 30, 2024 | -5.09 Mn |
| Jun 30, 2024 | -5.09 Mn |
| Mar 31, 2024 | -4.76 Mn |
| Mar 31, 2024 | -4.76 Mn |